Capricor Therapeutics (CAPR) is a San Diego-based clinical-stage biotechnology company developing cell and exosome-based therapies, led by deramiocel (CAP-1002), an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy. Shares traded at $9.15 at midday Wednesday, a gain of 8.80% from the prior session's close of $8.41, confirming a move clearly to the upside. The advance coincided with the withdrawal of the administration's nominee to run the FDA, which investors read as improving the odds for pending drug applications, alongside heavy pre-decision positioning ahead of the Nov. 22 PDUFA date for deramiocel.
The dominant catalyst was Washington, not the clinic. The White House withdrew Dr. Heidi Overton's nomination to lead the FDA on Wednesday amid concerns about congressional support, and small-cap biotechs with live regulatory files rallied sharply on the news. The logic is straightforward: any change to agency leadership creates uncertainty about the review posture that produced prior rejections. Both Replimune's RP1 and Capricor's deramiocel were declined during the previous FDA leadership, and investors now see a fresh leadership search as a reason to re-rate that pathway. The gains in RGNX, REPL and CAPR were broadly proportional to how binary each company's nearest decision is.
The move was amplified by the timing of the calendar. The FDA's target action date for deramiocel falls on Sunday, Nov. 22 — four days after today's session — leaving little room to adjust positioning. Capricor narrowed its application to preserving upper limb function in patients aged nine and older after a July advisory committee voted 9-3 that the evidence did not establish effectiveness for DMD-related cardiomyopathy. The HOPE-3 trial reported a 1.1-point advantage on the Performance of the Upper Limb 2.0 scale versus placebo with a p-value of 0.029, and 24-month open-label data showed decline slowing by 76% in patients who switched from placebo. Options activity has implied a move approaching 90% in either direction around the decision, which mechanically feeds sharp directional swings as traders pick sides.
Part of the gain is simple mean reversion. After jumping 26.5% on Nov. 11 following third-quarter results, the stock fell for three consecutive sessions, from $11.22 to $8.41 — a 25% drawdown that left it oversold into a binary event. The Nov. 16 close of $8.30 marked the low of that pullback, and today's move has reclaimed the $9 level. That sequence of sharp rallies followed by equally sharp retracements is characteristic of a heavily traded, event-driven small-cap rather than a fundamental re-rating.
Volume tracked roughly 3.7 million shares by early afternoon against an average daily turnover of about 4.7 to 5.2 million, putting the session on pace to finish meaningfully above normal. The advance was a biotech-specific move, matching the direction of other single-asset drug developers with pending decisions rather than broad market flows. Technically, the stock bounced off the $8.19 to $8.30 area that contained the November pullback and pushed back above $9, but it remains roughly 68% below where it started the year and about 77% beneath its 52-week high of $40.37. Market capitalization sits near $530 million, small enough that a modest inflow of capital produces an outsized percentage move.
The score runs from 0, meaning no meaningful news and a move that is routine for the stock, to 100, meaning transformative news and an extreme, rare price move. This event lands at 30 out of 100. The verified news is real but indirect: a change at the top of the FDA matters to sentiment, yet it alters nothing about the deramiocel data package itself, so catalyst strength is moderate. The price move of 8.80% was about 1.5 times the stock's average absolute daily change of 5.9% over the past 60 sessions, and 13 of those sessions produced moves of equal or larger size. Unusual relative to the market, yes; unusual relative to this stock, no. Modest news and an ordinary swing combine into a low-to-mid score.
The immediate focus is the FDA's action on or before Sunday, Nov. 22, with the approved label's scope — and whether the cardiomyopathy population is included — likely to matter more than the headline decision itself. A Priority Review Voucher, which the Rare Pediatric Disease designation may trigger, is a secondary value lever. Beyond the decision, investors will weigh roughly $198.5 million in cash as of Sept. 30, a third-quarter net loss of $42.7 million and a 10% workforce reduction taken to conserve capital. The contractual dispute with NS Pharma over U.S. distribution rights heads toward an arbitration hearing expected in mid-2027. Analyst coverage remains split, with several Buy ratings carrying targets far above the current price and at least one Hold, reflecting genuine disagreement about approvability. Next quarterly results are not expected until March 2027.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions earn a place in its curated Trending AI Robots section. Because these bots differ widely by strategy, timeframe, performance metrics and traded symbols, comparing them side by side helps investors see which approaches are working in the present tape rather than in theory. For event-driven names like this one, that context can be especially useful. Explore the Trending AI Robots page to see which strategies currently lead.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
The 10-day RSI Indicator for CAPR moved out of overbought territory on November 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 27 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CAPR as a result. In 67 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for CAPR turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
CAPR moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CAPR broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CAPR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for CAPR crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 232 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.125) is normal, around the industry mean (3.596). P/E Ratio (-3.673) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (443.347).
The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology